- In November 2024, Roche entered into an agreement to acquire Poseida Therapeutics for approximately USD 1 billion. This acquisition enhances Roche's capabilities in allogeneic cell therapies, particularly for oncology, immunology, and neurology. It aims to accelerate the development of off-the-shelf CAR-T therapies, benefiting patients by increasing treatment access and improving clinical outcomes. The transaction is expected to close in the first quarter of 2025
- In September 2024, Roche launched the first test to use its breakthrough TAGS technology for high throughput, simultaneous detection of 12 respiratory viruses. New TAGS (Temperature-Activated Generation of Signal) technology enabled up to 15 targets to be detected simultaneously in a single patient sample on the high throughput molecular diagnostic analysers cobas 5800, 6800 and 8800
- In March 2023, Roche announced that the U.S. FDA Oncologic Drugs Advisory Committee voted in favor of Polivy in combination with R-CHP for previously untreated diffuse large B-cell lymphoma (DLBCL). This combination showed a significant improvement in progression-free survival compared to the standard R-CHOP regimen, offering a promising first-line treatment option for DLBCL patients. The decision is expected to improve outcomes for patients with this aggressive cancer, which has seen limited progress in treatment over the past 20 years
- In March 2022, MDiaSorin’s Luminex received CE marking for its xMAP NxTAG Gastrointestinal Pathogen Panel (GPP), a multiplex test detecting 16 bacterial, viral, and parasitic pathogens in stool samples. Designed for the MAGPIX System, it delivers same-day results, enhancing rapid diagnosis, antibiotic stewardship, and high-throughput testing for clinical laboratories across Europe
- In May 2023, DiaSorin S.p.A. strengthens its partnership with MeMed by signing a distribution agreement for the MeMed BV test in Italy. This test, integrated with AI, differentiates bacterial from viral infections, aiding antibiotic decisions. Validated globally, it enhances patient management and supports efforts to combat antimicrobial resistance
Frequently Asked Questions
F. Hoffmann-La Roche Ltd (Switzerland), DiaSorin S.p.A (Italy), BIOMÉRIEUX (France), Thermo Fisher Scientific Inc. (U.S.), and QIAGEN (Germany) are the major companies in the Europe syndromic multiplex diagnostic market.
In September 2024, Roche launched the first test to use its breakthrough TAGS technology for high throughput, simultaneous detection of 12 respiratory viruses. New TAGS (Temperature-Activated Generation of Signal) technology enabled up to 15 targets to be detected simultaneously in a single patient sample on the high throughput molecular diagnostic analysers cobas 5800, 6800 and 8800.
The countries covered in the Europe syndromic multiplex diagnostic market are Germany, U.K., France, Italy, Spain, Russia, Netherlands, Switzerland, Turkey, Belgium, Sweden, Poland, Denmark, Norway, Finland, and Rest of Europe.
